1. |
McTague A, Howell KB, Cross JH, <italic>et al</italic>. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol, 2016, 15(3): 304-316.
|
2. |
Veeramah KR, O'Brien JE, Meisler MH, <italic>et al</italic>. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet, 2012, 90(3): 502-510.
|
3. |
Lindy AS, Stosser M B, Butler E, <italic>et al</italic>. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia, 2018, 59(5): 1062.
|
4. |
Meisler MH. SCN8A encephalopathy: Mechanisms and models. Epilepsia, 2019, 60(Suppl 3): 86-91.
|
5. |
Johannesen KM, Gardella E, Encinas AC, <italic>et al</italic>. The spectrum of intermediate SCN8A-related epilepsy. Epilepsia, 2019, 60(5): 830-844.
|
6. |
Encinas AC, Moore I KM, Watkins JC, <italic>et al</italic>. Influence of age at seizure onset on the acquisition of neurodevelopmental skills in an SCN8A cohort. Epilepsia, 2019, 60(8): 1711-1720.
|
7. |
Johannesen KM, Gardella E, Scheffer I, <italic>et al</italic>. Early mortality in SCN8A-related epilepsies. Epilepsy Research, 2018, 143: 79-81.
|
8. |
Atkin TA, Maher CM, Gerlach AC, <italic>et al</italic>. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy. Epilepsia, 2018, 59(Suppl 2): 802-813.
|
9. |
Boerma RS, Braun KP, van den Broek MP, <italic>et al</italic>. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics, 2016, 13(1): 192-197.
|
10. |
Brunklaus A, Du J, Steckler F, <italic>et al</italic>. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. Epilepsia, 2020, 61(3): 387-399.
|
11. |
Schreiber JM, Tochen L, Brown M, <italic>et al</italic>. A multi-disciplinary clinic for SCN8A-related epilepsy. Epilepsy Res, 2020, 159: 106261.
|